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New direct-acting antiviral (DAA) agents are in development or already approved for
the treatment of chronic hepatitis C virus (HCV) infection. The effectiveness of these
drugs is related to the previous existence of resistant variants. Certain clinical
conditions can allow changes in immunological characteristics of the host and even
modify genetic features of viral populations. The aim of this studywas to performHCV
molecular characterization from samples of end-stage renal disease patients on
hemodialysis (ESRD-HD). Nested PCR and Sanger sequencing were used to obtain
genetic information from the NS5B partial region of a cohort composed by 86
treatment-naïve patients. Genomic sequences from the Los Alamos databank were
employed for comparative analysis. Bioinformatics methodologies such as phyloge-
netic reconstructions, informational entropy, and mutation analysis were used to
analyzedatasets separatedbygeographical location,HCVgenotype, and renal function
status. ESRD-HD patients presented HCV genotypes 1a (n = 18), 1b (n = 16), 2a (n = 2),
2b (n = 2), and 3a (n = 4). Control subjects were infected with genotypes 1a (n = 11), 1b
(n = 21), 2b (n = 4), and 3a (n = 8). Dataset phylogenetic reconstruction separated HCV
subtype 1a into two distinct clades. The entropy analysis from the ESRD-HD group
revealed two amino acid positions related to an epitope for cytotoxic T lymphocytes
and T helper cells. Genotype 1a was found to be more diverse than subtype 1b. Also,
genotype 1a ERSD-HD patients had a higher mean of amino acids changes in
comparison to control group patients. The identification of specific mutations on
epitopes and high genetic diversity within the NS5B HCV partial protein in
hemodialysis patients can relate to host immunological features and geographical
distribution patterns. This genetic diversity can affect directly the new DAA's
resistance mechanisms.
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1 | INTRODUCTION
Patients with end-stage renal disease (ESRD) under hemodialysis (HD)
are exposed to an increased risk of acquiring pathogens infections
through nosocomial ways, including viral hepatitis infections.1,2 The
occurrence of hepatitis C virus (HCV) in HD patients is variable among
different countries and medical centers, mostly associated with
medical assistance quality.3 Nosocomial infection is a larger problem
when dealing with disease without a vaccine, and recent researches
indicate that this way of transmission is still a great risk for HCV
infection and outbreaks inside hemodialysis units.4–7 Patients with
ESRD infected with HCV are associated with a greater morbidity and
mortality.8 The kidney function in the ESRD population plays a crucial
role in the HCV treatment pharmacokinetics.9 Ribavirin-induced
anemia is caused by the accumulation in erythrocytes subsequent to
active unidirectional transmembrane transport.10 Patients with kidney
disease tend to have baseline anemia, turning the conventional
treatment hard to manage on chronic renal patients. ESRD-HD
patients also present platelet function abnormalities, lower amino-
transferase activity, and lower humoral response as factors that can
aggravate HCV prognosis.11
The viral polymerase lacks of proofreading function and high
replication rate contribute to a high genetic diversity even between
variants from the same viral subtype. For HCV, the estimatedmutation
rate in vivo was placed as 1.15 ± 0.2 × 10−4 substitutions per site
replicated,12,13 creating a viral complexity genetic information on a
host called quasispecies.14 Different factors can prevent the existence
of this high diversity on the host, such as immunological pressures,
good replication fitness by the virus to keep infecting new cells, and the
treatment that can cause an adaptive effect on the viral population.
HCV populations of high genetic diversity can be found on chronic
patients with normal renal function and presenting no immunological
disorders.14–16 High genetic diversity is seen in phylogeographic
patterns, genotype separation, and diverse subtypes.17 The absence of
selective pressure caused by the lack of immunological function can
also lead to a higher mutation fixation rate, representing a higher
complexity on the HCV quasispecies composition in ESRD-HD
patients.18
With new direct-acting antiviral (DAA) drugs for HCV infection
treatment, resistance issues became easier to cope with.
Resistance-associated variants (RAV) searches for protease,
polymerase, and NS5A inhibitors from sequence databases19–21 and
untreated patients from different locations22–28 have already been
performed. The presence of lower genetic barriers on specific
subtypes is caused by the fixation of synonymous mutations on
resistance-associated codons19 and the recent communication of
long-termpersistence ofNS5A drug resistancemutations after the end
of treatment29 raise important questions about new treatment
strategies.
Data associating viral treatment resistance to genetic diversity
from intra-host populations and the intrinsic difficulties to treat renal
disease patients raise questions about the real genetic diversity from
that special population.
The aim of this study was to characterize the genetic diversity and
resistance mutation frequency of the ERSD-HD patients from the
gastroenterology department of the Universidade Federal de São Paulo
in relation to chronic-infected patients with normal renal function.
2 | MATERIALS AND METHODS
Plasma samples of 86 HCV chronically infected patients were drafted
at gastroenterology department of Universidade Federal de São Paulo
(UNIFESP; São Paulo, Brazil). Patients were separated into two groups.
The control group composed of subjects with normal renal function,
chronical HCV infection, and the absence of coinfection. TheHDgroup
was formed by HCV chronically infected patients undergoing
hemodialysis treatment sessions for at least 1 year. The 1-year period
of HDwas chosen to able the viral population to establish a genetically
diverse population according to the host-blunted immunological
profile. Written informed consent was obtained from each patients
and the study protocol was approved by the hospital ethics board in
accordance with the 1975 Declaration of Helsinki.30
HCV RNA extractions were performed using the QIAamp Viral
RNA Kit (Qiagen [Uniscience do Brasil], Sao Paolo, Brazil) starting with
140 μL of serum, according to the manufacturer's recommendations
and cDNA was produced using reverse transcriptase (Invitrogen) with
random primers.
A two-step (nested) PCR protocol was used for the NS5B gene
primer set (NS5B_243/NS5B_242 for the first PCR reaction and
NS5B_Pr3/NS5B_Pr5 for the second reaction).31,32 The fragment
amplified from the NS5B polymerase has already been tested for
phylogenetic signal intensity.33 PCR products were purified using
IllustraGFXPCRPurificationKit (GEHealthcare, Buckinghamshire, UK).
Capillary electrophoresis sequencing was performed with ABI
PRISM BigDye Terminator Cycle Sequencing Ready Reaction Kit (Life
Technologies, Carlsbad, CA) on an ABI PRISM 3500 automatic
sequencer (Life Technologies) according to the manufacturer's
instructions. All the sequences were submitted to GenBank under
the accessions numbers KP057692-KP057795.
After sequencing, contigs were created using Phred/Phrap/
Consed.34,35 For accurate genotyping, the samples contigs and 14
reference sequences (AF009606_1a, D90208_1b, AY05129_1c,
D14853_1c, D00944_2a, D10988_2b, AB047639_2a, D50409_2c,
D17763_3a, D49374_3b, D28917_3a, Y11604_4a, Y13184_5a,
Y12083_6a, D84262_6b e EF108306_7a) were aligned using Clustal
X 2.0.36 The best substitution model was identified using JModelTest
2.37 A phylogenetic tree was estimated from a HKY DNA substitution
model38 with 1000 bootstrap pseudo replicates39 using Seaview 4.0
and PHYML package with Neighbor Joining method.40
A total of 82 Brazilian sequences belonging to subtype 1a and 161
sequences of subtype 1b were obtained with the in silico search of
Brazilian HCV polymerase fragment sequences on Los Alamos HCV
database (https://hcv.lanl.gov/content/index)41 and Genbank (https://
www.ncbi.nlm.nih.gov/genbank/). Datasets of subtypes 1a and 1bwith
in silico and target sequencesobtainedon thatworkwere used toobtain
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a more detailed genetic reconstruction analysis with local geographical
information. Both datasets demonstrated a goodphylogenetic signal for
the fragment. Phylogenetic reconstruction by maximum likelihood was
made with both subtypes with a HKY+I+G model38 as indicated by the
software jModeltest 2.0.37 Clade patterns among sequences from
genetics databases, control patients, and HD patients were analyzed.
The genetic diversity of both groups was obtained comparing the
number of nucleotide and amino acids alterations on datasets
separated by genotype according to the reference sequence clade
formation pattern. Themeans of nucleotide and amino acid divergence
between sequences groups were tested for normality and then
compared with Student's t-test for no related samples with SPSS
software.42 P values lower than 0.05 were used to determine whether
genetic changes between genotypes and analysis groups were
significantly different.
3 | RESULTS
Genetic sequences from86 plasma sampleswere obtained after Phred/
Phrap screening and contig assembly, 42 patientswith ESRD (HDgroup)
and 44 patients with normal renal function (control group). Neighbor
joining phylogenetic reconstruction was performed with 16 reference
sequences to generate genotype and subtype for each sample. All the
clades that characterized genotypes and subtypes separation had
Bootstrap value greater than 70 (Suplemmentary Figure 1).
HD group patients presented HCV genotypes 1a (n = 18), 1b
(n = 16), 2a (n = 2), 2b (n = 2), and 3a (n = 4). Control subjects were
infectedwith genotypes 1a (n = 11), 1b (n = 21), 2b (n = 4), and 3a (n = 8)
(Table 1).
The 1a subtype dataset phylogenetic reconstruction demon-
strated 16 sequences from this work with a common ancestral origin
(eight monophyletic clades). Of the eight monophyletic clades, seven
of them were made of sequences from the same analysis group (six
clades formed with HD group sequences and one clade with control
group sequences). Only one of the eightmonophyletic clades is formed
by sequences from different analysis group (HD and control group).
Thirteen sequences from our 1a patient's sequences formed clades
with local databank genetic sequences or as clades outgroups.
Subtype 1b phylogenetic reconstruction presented only two
clades with monophyletic origin between the two groups analyzed.
One of the clades is composed of two HD group patients and another
clade is composed of two sequences from different analysis group.
Genotype 1b remaining sequences (n = 33) formed clades with genetic
database sequences (Figure 1).
In both genotypes, none of HD group patients who formed
monophyletic clades were from the same dialysis center.
Informational entropy analysis was realized on the NS5B
polymerase fragment of subtypes 1a and 1b separated by patient's
groups and database sequences. The search aimed for amino acid
positions with higher entropy values only present on HD group HCV
sequences, not on control and genetic database sequences. Genotype
1a group presented two positions with entropy peaks higher than 0.2
bits (23 and 26 of the fragment, 2668 and 2671 from H77 sequence
reference). Subtype 1b sequences presented a similar profile with one
entropy peak position (25 from the fragment, 2670 from H77
reference) only on HD group. A second position close to the first
presented an entropy peak only on group HD and database sequences
(27 from the fragment, 2672 from H77 reference) absent on Brazilian
sequences (Figure 2).
All four positions are closely related to a particular epitope for
cytotoxic T lymphocytes and T helper cells recognition (CCDLDPQAR-
VAI; positions 2662-2673 in the H77 reference sequence) (Figure 2).
To assess genetic diversity, the mean of amino acid and nucleotide
changes using the subtype reference sequence was made (AF009606
for 1a subtype and D90208 for 1b). The mean changes were
significantly higher (P value < 0.05) on subtype 1b than subtype 1a
in both the nucleotides (12.75 ± 3.4 vs. 30.42 ± 3.7; P > 0.001) and
amino acids changes (2.25 ± 1.2 vs. 6.67 ± 0.9; P > 0.001) (Figure 3).
After that analysis, the mean of amino acid and nucleotide changes
using the subtype reference sequence as a model for the count was
made on datasets separated for subtypes and using both analyses
groups (Figure 4). Nucleotide count changes were significantly higher
for HD group on subtype 1a (14.53 ± 2.4 vs. 10 ± 2.8; P < 0.0001) and
subtype 1b (32.50 ± 1.7 vs. 28.89 ± 4.0; P < 0.004). Amino acid changes
were only significant on subtype 1a (1a: 2.53 ± 1.2 vs. 1.82 ± 1.0;
P < 0.001/1b: 7 ± 0.96 vs. 6.4 ± 0.9).
4 | DISCUSSION
Since the start of INF and RBV treatment, different factors influenced
how resistance is treated. HCV quasispecies genetic diversity studies
are focused on proteins as NS5A and envelope proteins (E1 and E2),
usually associated with INF resistance.43,44 Evidence of high
quasispecies diversity on pretreatment populations has already been
related to the poor response to INF and Ribavirin treatment, although
the lack of direct association with resistance to treatment and genetic
mechanisms.45–48 The genotype distribution on our samples was in
accordance with another works that place genotype 1 as the most
present in Brazil and the presence of genotypes 2 and 3 on a lower
frequency.49,50
HCVgenotypedistributiononHDpatients canbe related tospecific
event transmissions on medical units.51 Our data demonstrated a
TABLE 1 Genotype distribution between the HD and control
patients groups
Genotype HD Group Control Total
1a 18 11 29
1b 16 21 37
2a 2 - 2
2b 2 4 6
3a 4 8 12
Total 42 44 86
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homogeneity when considering subtypes distribution between groups
analyzed, what can be related to the small number of patients in both
groups and subtypes. Unlike hepatitis B genotype distribution between
hemodialysis patients that present the genotype D as the mostly
associated with that particular group,1,52 our group of patients
demonstrated a similar genotypedistributionwith normal renal function
and ESRD patients.
Quasispecies diversity is an adaptive mechanism characterized by
the virus capacity to escape from immunological host pressures also
considered on the new HCV DAA treatments and the acquisition of
specific resistancemutations.Resistanceassociatedvariantsareseenon
minor viral populations in the patient that rise along the treatment.
During the treatment, the resistance-associatedpopulationsenhance its
frequency thought lack of competition, even with lower replication
fitness.53 One of the differences between subtypes observed in this
work is thehighergeneticdiversitydemonstratedasmeanofchangeson
amino acid and nucleotide differences. Romano and Carvalho-Mello54
proposed that phylodynamics differences can be explained by the older
origin of subtype 1b. If so, a saturation rate in themutations couldmake
difficult tovisualize genetic patterns of changesondifferent groups.Our
analysis demonstrated a clear and significant highermean of changes on
subtype 1a samples.
HCV intrinsic capacity to create a high genetic diversity
contributes to several adaptive mutations that can lead to a escape
from host's immune system. One of the features caused by the high
genetic diversity is amino acid changes in epitopes. Studies already
demonstrated virus neutralizing antibody response as an important
viral evolution variable.55 Modifications on epitopes regions has been
employed by the virus as a way to blunt regulation of T cell response
and avoid early virological clearance, although 20% of patients have
FIGURE 1 Phylogenetic reconstruction for both subtypes 1a and 1b made by maximum likelihood method and HKY+G+I evolutionary
model. Subtype 1a analysis employed 111 sequences and subtype 1b, 198. Patients from control group are in blue, patients from
hemodialysis group on red, and Brazilian database sequences on green. Bootstrap percentage are on the respective node
540 | ALVES DA SILVA ET AL.
early virological clearance and are protected from reinfection
indicating the possibility of a vaccine development.56–58 It remains
unclear how the evolution of epitopes regions on different host
immune system pressures takes place.
The Shannon informational entropy is a tool that can calculate the
amount of informational complexity on homologue amino acids and
nucleotides sequences. Epitope regions exhibit a tendency to have
lowerentropyvalues, consequently, ahigher informational conservation.
FIGURE 2 Informational Shannon entropy graphs for all sequences from genotype 1 obtained in this work for HD, control, and database
Brazilian sequences groups. The entropy is represented in bits for each residue numbers in amino acids positions from the fragment analyzed
FIGURE 3 Graph of means of amino acids and nucleotide alterations from subtypes 1a and 1b sequences of groups HD (n = 31) and
control group (n = 30). The mean difference was statistically significant by the t-Student test for non-related samples with P < 0.0001
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This can be explained by the necessity of protein structural stability for
cell recognition.59 In our work, entropy peaks were found on two
positions related to the NS5B recognition epitopes.
Patients under hemodialysis present several complications,
including a blunted immunological system.18 The absence of some
immunological pressure on the viral evolution can be the main reason
to the nucleotide changes accumulation. The non-significant amino
acids difference between ERSD-HD and control group can be related
to the conformational protein conservation necessity to maintain its
function. The increased nucleotide genetic diversity can be associated
with factors as genetic memory by the presence of degenerates
codons that are prone to resistance development or that can cause an
easier escape from the immune system, making virions better fitted to
high selective pressures situations. The hypothesis that part of the
difficulties to obtain sustained virological response in hemodialysis
patients in comparison to normal kidney function patients could be
related to the larger capacity of the virus to acquire epitope escape
mutations is sustained by these findings.
The RNA-dependent RNA-polymerase HCV protein is a highly
functional protein that demands a certain level of conservation to
maintain a high replication fitness, specifically on the active site.60
Necessity of high replication fitness through informational conserva-
tion is opposed to the challenge imposed by the immunological system.
As a consequence of host's immunological pressure absence in ERSD-
HD patients, viral particles are free to accumulate mutations through
the RNA molecule enhancing the chance to present nucleotide and
amino acid changes on recognitions epitopes. Unless those mutations
alter the replication fitness, the tendency to maintain polymorphic
populations is increased. Admitting the hypothesis that genetic diverse
populations have a more chance to escape antiviral treatment,61
patientswho undergo hemodialysis aremore likely to present that type
of complexity viral population.
5 | CONCLUSION
Despite the clade formation pattern of HCV subtype 1a from the same
hemodialysis patient analysis group, no relations about the hemodial-
ysis centers were found, discarding nosocomial transmission between
patients. The minor 1a subtype genetic diversity can be associated to
the more recent origin, and less saturated mutation rate between
isolates. ERSD-HD patients are known to have a blunted immunologi-
cal system and the significant differences on nucleotide mutations
seen on this work could be related to minor immunological pressures
imposed by that specific population.
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